Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer

Hunan Province Tumor Hospital1 site in 1 country70 target enrollmentMarch 24, 2020

ConditionsNon Small Cell Lung Cancer

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Non Small Cell Lung Cancer
Sponsor: Hunan Province Tumor Hospital
Enrollment: 70
Locations: 1
Primary Endpoint: PFS
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This study aims to explore the efficacy and safety of Pembrolizumab Combined With Double Platinum-Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer

Detailed Description

Inclusion criteria: diagnosed with Non-small cell lung cancer EGFR and ALK and ROS1 negative Treatment naive Potentially Resectable identified by MDT

Registry

clinicaltrials.gov

Start Date

March 24, 2020

End Date

March 24, 2025

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Hunan Province Tumor Hospital

Responsible Party

Principal Investigator

Yongchang Zhang

professor

Hunan Province Tumor Hospital

Eligibility Criteria

Inclusion Criteria

•≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
•Potentially Resectable NSCLC
•Treatment Plan is Crizotinb or Standard Chemotherapy